%0 Journal Article
%A Hilvo, Mika
%A Meikle, Peter J
%A Pedersen, Eva Ringdal
%A Tell, Grethe S
%A Dhar, Indu
%A Brenner, Hermann
%A Schöttker, Ben
%A Lääperi, Mitja
%A Kauhanen, Dimple
%A Koistinen, Kaisa M
%A Jylhä, Antti
%A Huynh, Kevin
%A Mellett, Natalie A
%A Tonkin, Andrew M
%A Sullivan, David R
%A Simes, John
%A Nestel, Paul
%A Koenig, Wolfgang
%A Rothenbacher, Dietrich
%A Nygård, Ottar
%A Laaksonen, Reijo
%T Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients.
%J European heart journal
%V 41
%N 3
%@ 1522-9645
%C Oxford
%I Oxford University Press
%M DKFZ-2019-01601
%P 371-380
%D 2020
%Z 2020 Jan 14;41(3):371-380
%X Distinct ceramide lipids have been shown to predict the risk for cardiovascular disease (CVD) events, especially cardiovascular death. As phospholipids have also been linked with CVD risk, we investigated whether the combination of ceramides with phosphatidylcholines (PCs) would be synergistic in the prediction of CVD events in patients with atherosclerotic coronary heart disease in three independent cohort studies.Ceramides and PCs were analysed using liquid chromatography-mass spectrometry (LC-MS) in three studies: WECAC (The Western Norway Coronary Angiography Cohort) (N = 3789), LIPID (Long-Term Intervention with Pravastatin in Ischaemic Disease) trial (N = 5991), and KAROLA (Langzeiterfolge der KARdiOLogischen Anschlussheilbehandlung) (N = 1023). A simple risk score, based on the ceramides and PCs showing the best prognostic features, was developed in the WECAC study and validated in the two other cohorts. This score was highly significant in predicting CVD mortality [multiadjusted hazard ratios (HRs; 95
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:31209498
%R 10.1093/eurheartj/ehz387
%U https://inrepo02.dkfz.de/record/144050